Text Size

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

This study has been terminated.
Sponsor:
Collaborator:
ZymoGenetics
Information provided by:
EMD Serono
ClinicalTrials.gov Identifier:
NCT00573157
First received: December 11, 2007
Last updated: May 3, 2011
Last verified: May 2011
History of Changes
  Purpose

The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in patients with active lupus nephritis when taken in addition to mycophenolate mofetil and corticosteroids


Condition Intervention Phase
Lupus Nephritis
 Drug: MMF
Drug: Atacicept plus MMF
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by EMD Serono:

Primary Outcome Measures:
  • The primary outcome is the proportion of subjects with improvement in renal response to treatment. [ Time Frame: The final measurements is at 52 weeks, and there is a total of 24 with follow-up after that ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with normalization of renal function; frequency of new lupus flares [ Time Frame: Same as for primary ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: December 2007
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Mycophenolate mofetil(MMF) alone
 Drug: MMF
Mycophenolate mofetil(MMF)
Active Comparator: 2
Mycophenolate mofetil(MMF) plus atacicept
 Drug: Atacicept plus MMF
Atacicept plus Mycophenolate mofetil (MMF)

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of SLE satisfying at least 4 out of the 11 American College of Rheumatology (ACR) criteria (Appendix B)
  • Renal biopsy performed consistent with active International Society of Nephrology/Renal Pathology Society (ISN/PRS) class III or IV LN

Exclusion Criteria:

  • Estimated glomerular filtration rate (GFR) ≤30 mL/min per 1.73 m2
  • Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment
  • Any treatment with MMF, azathioprine, or cyclophosphamide within the last 6 months, or known hypersensitivity to MMF or atacicept.
  • Any prior treatment with abatacept, rituximab, belimumab, or other B cell modulating agents.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573157

Locations
United States, Louisiana
Tulane University Hospital and Clinic Department of Internal Medicine
New Orleans,, Louisiana, United States
Northwest Louisiana Nephrology Research
Shreveport, Louisiana, United States, 71101
United States, Michigan
Wayne State University Lupus Database Departments of Internal Medicine and Obstetrics & Gynecology Division of Rheumatology Wayne State University School of Medicine
Detroit, Michigan, United States
United States, New York
The Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Seligman Center for Advanced Therapeutics
New York, New York, United States, 10003
United States, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27109
United States, Ohio
Rheumatology Clinical Research Unit, Division of Rheumatology University Hospitals Case Medical Center
Beachwood, Ohio, United States, 44122
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States, 45267
The Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Southwest Rheumatology and Research Group, LLC
Middleburg Heights, Ohio, United States, 44130
United States, South Carolina
1711 St. Julian Place
Columbia, South Carolina, United States, 29204
ACME Research, LLC
Orangeburg, South Carolina, United States, 29118
Czech Republic
Institute of Rheumatology
Prague, 128 50, Czech Republic
Malaysia
Hospital Sultanah Bahiyah
Kedah, Malaysia
Hospital University Kebangsaan Malaysia
Kuala Lumpur, Malaysia
University of Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Singapore
Singapore General Hospital
Singapore, Singapore
Changi General Hospital
Singapore, Singapore
Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan
Sponsors and Collaborators
EMD Serono
ZymoGenetics
Investigators
Study Director: Jan L Hillson, MD ZymoGenetics
  More Information

No publications provided by EMD Serono

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Sally Anne Jones, Clinical Trial Manager, Clinical Trials Management, Zymogenetics
ClinicalTrials.gov Identifier: NCT00573157     History of Changes
Other Study ID Numbers: 28113, 493G01
Study First Received: December 11, 2007
Last Updated: May 3, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lupus Nephritis
Nephritis
Glomerulonephritis
Kidney Diseases
Urologic Diseases
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Mycophenolate mofetil
 Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 19, 2013